Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Chemokine receptor CXCR4 is expressed on malignant tumors like glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL).
• Existing imaging agents for CXCR4 have limitations in visualizing brain tumors due to the blood-brain barrier (BBB) and intracellular receptor localization.

Purpose of the Study:

• To synthesize and evaluate novel iodinated and brominated cyclam derivatives for imaging CXCR4 expression in brain tumors.
• To overcome challenges associated with BBB penetration and intracellular uptake for improved diagnostic imaging.

Main Methods:

• Synthesized six cyclam derivatives with high affinity for CXCR4, designed for lipophilicity to cross the BBB.
• Tested radiolabeled derivatives in CXCR4(+) and CXCR4(-) cell lines and established murine models of intracranial GBM and PCNSL.
• Selected 76Br-HZ270-1 for further evaluation based on initial uptake studies in subcutaneous tumor models.

Main Results:

• Halogenated cyclam derivatives demonstrated high affinity for CXCR4.
• 76Br-HZ270-1 showed high uptake and low non-specific uptake in subcutaneous tumor models.
• Imaging of intracranial U87-CXCR4 and PCNSL #15 tumors with 76Br-HZ270-1 was unsuccessful via intravenous or spinal-CSF injection.

Conclusions:

• Halogenated cyclam derivatives successfully imaged CXCR4 in subcutaneous tumors but not in CNS tumors.
• The failure in CNS tumors was attributed to the radioligands' hydrophilicity and the presence of intact blood-brain/tumor barriers.
• The study highlights challenges in developing effective CXCR4-targeting radiotracers for brain tumor imaging.